Fierce Pharma

SEPTEMBER 7, 2023

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma 335

Biopharma Pharma 335

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246

Biopharma Patients 246

Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting 265

Prospecting Biopharma Pharma Healthcare 265

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 295

Biopharma 295

Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 238

Biopharma Pharmaceutical 238

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma 293

Biopharma Sales 293

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma 262

Biopharma Manufacturing 262

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 299

Biopharma 299

Fierce Pharma

JUNE 26, 2023

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma 182

Biopharma 182

Fierce Pharma

NOVEMBER 27, 2023

It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly’s fortunes have turned quickly. | Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.

Biopharma 299

Biopharma Pharma 299

Fierce Pharma

SEPTEMBER 25, 2023

A who’s who of biopharma companies have backed a push to rai | A who’s who of biopharma companies have backed a push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate the community about risk factors, early warning signs and screening.

Biopharma 208

Biopharma Education Pharma 208

European Pharmaceutical Review

JUNE 7, 2023

The global biopharma industry’s resilience has decreased since 2021, a report by Cytiva has found. Using feedback from 1250 pharma and biopharma executives in 22 countries, the research sought to find out how has the biopharma industry has evolved over the past two years and what areas the industry should seek to improve.

Biopharma 84

Biopharma Government Manufacturing Pharma 84

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma 237

Biopharma 237

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma 211

Biopharma 211

Fierce Pharma

AUGUST 15, 2023

As the coronavirus surged and subsided, several biopharma companies experienced exaggerated revenue spikes and troughs. Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far.

Biopharma 246

Biopharma Sales Pharma 246

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma 263

Biopharma 263

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma 218

Biopharma 218

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma 217

Biopharma 217

Fierce Pharma

NOVEMBER 30, 2023

we're highlighting two weeks' worth of biopharma news related to Asia. Because of the recent Thanksgiving holiday in the U.S., AstraZeneca in-licensed a KRAS G12D inhibitor from China's Usynova. BeiGene bought global rights to a CDK2 inhibitor in a deal worth up to $1.3 market at a 20% discount to Merck's Keytruda.

Biopharma 228

Biopharma Pharma Marketing 228

Fierce Pharma

SEPTEMBER 11, 2023

The adoption of technology and data by biopharma is driving a digital transformation in manufacturing, accelerating the process of bringing molecules from benchside to bedside. My name is Gaurav Marya. I am the Strategic Business Unit Head and Global Head of Mergers and Acquisitions for Life Sciences at Cognizant. |

Manufacturing 200

Manufacturing Biopharma Pharma 200

Fierce Pharma

MAY 9, 2023

We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56

Biopharma 162

Biopharma 162

MedCity News

OCTOBER 3, 2023

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

Biopharma 112

Biopharma Pharma 112

Fierce Pharma

DECEMBER 19, 2023

As the biopharma world readies for the turn of the calendar, the all-too-familiar topic of drug pricing once again presents an industry-wide overhang. Based on the series of measures centered on U.S. drug prices coming out of Washington, the Biden administration is clearly emboldened on the topic.

Biopharma 195

Biopharma Pharma 195

Fierce Pharma

MARCH 11, 2024

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended.

FDA 350

FDA Biopharma 350

Fierce Pharma

MAY 18, 2023

The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13

Biopharma 147

Biopharma 147

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

Competition 93

Competition Biopharma Government Manufacturing 93

Fierce Pharma

APRIL 12, 2024

Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters.

Biopharma 228

Biopharma 228

European Pharmaceutical Review

MARCH 31, 2023

GlobalData Pharma Intelligence Center Deals Database found: SVB Financial Group and its subsidiaries were involved in more than $1.4 A Danish pharma company developing peptide-based medicines, expects to recover its $23.4 The post Biopharma could reap benefits from SVB UK acquisition appeared first on European Pharmaceutical Review.

Biopharma 96

Biopharma Pharma Networking Marketing 96

Pharmaceutical Technology

JUNE 24, 2022

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.

Biopharma 64

Biopharma Pharma Pharmacology Healthcare 64

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.

Biopharma 59

Biopharma Competition Prescription Education 59

Fierce Pharma

FEBRUARY 21, 2024

In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.

Leads 295

Leads Biopharma Sales 295

Fierce Pharma

JUNE 6, 2023

Novo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million. Paratek's key selling point is its antibiotic, Nuzyra, which was expected to garner $500 million in peak sales at the time of its 2018 approval.

Biopharma 251

Biopharma Pharma Sales 251

European Pharmaceutical Review

JUNE 8, 2023

A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.

Biopharma 88

Biopharma Government Training Education 88

Fierce Pharma

JANUARY 23, 2023

Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32

Biopharma 130

Biopharma 130

European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s

Biopharma 90

Biopharma Pharmaceutical Medicine Manufacturing 90

Fierce Pharma

DECEMBER 22, 2023

Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 348

Biopharma 348

Fierce Pharma

MARCH 28, 2024

Authors: | Gain the competitive edge with accurate probability of success assessments to uncover undervalued companies and early-stage assets for acquisitions.

Biopharma 215

Biopharma Competition 215